The CIPHER trial, sponsored by Shahid Baba at the University of Louisville, investigates the effects of carnosine supplementation in patients with PAD, a condition affecting millions globally. If successful, this trial could position carnosine as a novel therapeutic option in the PAD market, which currently lacks effective non-invasive treatments. The study's collaboration with the NIH and NHLBI enhances its credibility and potential for funding and support. Given the increasing prevalence of PAD and the aging population, a positive outcome could lead to significant commercial opportunities, especially in the dietary supplement and pharmaceutical sectors. However, competition from existing PAD treatments and emerging therapies must be monitored closely.